![\"Donut](\"https://www.pheonixresearch.com/wp-content/uploads/2026/11/ivd-segment-share-2033-scaled.webp\")
This market has twelve participants of tier-one scale and no concentration at the level of the technology. Every one of the twelve can measure an analyte. What is concentrated is the installed base, and the installed base is what decides who earns the annuity that follows.
Platform and reagent majors place instruments and sell the consumables that run on them: Roche, Danaher, Abbott, Siemens Healthineers, Thermo Fisher, bioMerieux, Sysmex, Werfen, BD, Hologic, QIAGEN and QuidelOrtho. Their costs are manufacturing, instrument placement at or below cost, field service and tender participation. Their revenue is a price per reagent and per test, and it recurs for as long as the instrument stays installed.
The long tail is the other 43% of the market: Chinese domestic manufacturers, Japanese and Korean specialists, Indian and Brazilian suppliers, and the smaller European houses. Their cost base is a fraction of the multinationals', they compete almost entirely on price, and they win exactly where a procurement office sets the price in advance. The Jiangxi biochemical alliance, in which 154 manufacturers won 2,314 specifications at an average cut of 70%, is the clearest illustration available of how that layer takes share: not by out-innovating the majors, but by being able to survive a price the majors cannot.
| Participant | Attributed 2025, USD m | Share of base | Reported growth |
|---|---|---|---|
| Roche Diagnostics | 15,924 | 14.7% | +2% CER, -3% CHF |
| Danaher Diagnostics | 9,941 | 9.2% | +1.6% |
| Abbott Diagnostics | 8,937 | 8.3% | -4.5% organic |
| Siemens Healthineers Diagnostics | 4,912 | 4.5% | +0.4% comparable |
| Thermo Fisher Specialty Diagnostics | 4,676 | 4.3% | +3% organic |
| bioMerieux (clinical) | 3,679 | 3.4% | +6.2% organic |
| Sysmex (clinical) | 3,399 | 3.1% | +5.2% on guidance |
| QuidelOrtho | 2,730 | 2.5% | -1.9% |
| Werfen | 2,408 | 2.2% | +3.3% organic |
| BD Diagnostic Solutions | 1,838 | 1.7% | -0.7% FXN |
| Hologic Diagnostics | 1,827 | 1.7% | +2.5% |
| QIAGEN (clinical) | 1,254 | 1.2% | +5% CER |
| Top five | 44,390 | 41.1% | - |
| Top twelve | 61,525 | 57.0% | +1.2% weighted |
The largest participant is among the slowest and the seventh-largest is the fastest. That is not a coincidence and it is not a comment on competence. Roche's 14.7% share is built on a core laboratory franchise that was flat for the year; bioMerieux's 3.4% share is built on syndromic cartridges growing at double digits. The first is a mature annuity defended on price, the second is a growing annuity defended on menu.
Roche is simultaneously the largest participant in this market and the one with the most visible policy exposure. Its diagnostics division grew 2% at constant exchange rates and fell 3% in Swiss francs, and the whole of the shortfall is one geography: China down 24% and Asia-Pacific down 12%, against mid-single-to-low-double-digit growth in every other region, and +7% for the division excluding China. Immunodiagnostics fell 3% inside a flat Core Laboratory, which is where a reagent price cut lands first.
The same disclosure also shows the defence. Molecular Laboratory grew 4% on blood screening, Pathology Laboratory grew 14% behind companion diagnostics at +25% and advanced staining at +10%, and clinical chemistry grew 7% inside a flat Core Lab. A franchise that broad does not lose a geography, it re-mixes around it. The fragility is that the re-mix is slower than the price cut.
Danaher is the most instructive competitor in the market because it has converted instrument placement into a structural position. Cepheid's installed base is above 60,000 instruments, tripled since 2020, carrying more than 30 FDA-cleared assays and roughly USD 1 billion of sustainable incremental annual revenue on the company's own framing. Sexual health assays grew approximately 20% in the third quarter of fiscal 2025. Alongside it, Radiometer in blood gas and Leica Biosystems in anatomic pathology are each separately described as more than USD 1 billion businesses, and Leica is the vehicle for digital pathology.
That is three different annuity structures - a cartridge base, a blood gas base and a pathology base - in one segment, and it is why Danaher's diagnostics revenue grew 1.6% in a year when the market grew about 2%. The moat is not the assay. It is the fact that removing a Cepheid from a molecular laboratory requires someone to decide to do it.
In 46 depth interviews across eleven markets, the mechanism of share change was described consistently and it was not clinical superiority. It was contract structure. Laboratories are moving from single-vendor commitments towards multi-vendor arrangements precisely so that a reagent price can be re-tendered without losing the platform, and the buying metric quoted most often was cost per reportable result rather than price per test or instrument price. That single shift explains why menu breadth is worth more than assay performance: a laboratory that buys on cost per reportable result is buying throughput, uptime and menu coverage, and it will pay a premium for a platform that never stops.
The value chain in in vitro diagnostics runs from a reagent lot to a reportable result, and the margin is not distributed where the manufacturing is. Almost every percentage point of profit in this market is earned in the annuity that follows an instrument placement.
Reagent manufacturing. Antibodies, enzymes, oligonucleotides, buffers and the plastics they are carried in. Gross margins here are high and reasonably stable, but the manufacturing cost is a small fraction of what the laboratory eventually pays, because the antibody is not the product - the validated performance on a specific analyser is.
Instrument placement. The analyser is sold near cost, leased, or placed under a reagent commitment. Siemens states the model in its own annual report: long-term contracts that begin with an instrument placement and continue with reagent sales, generating a predictable revenue stream. The instrument is a toll booth that is given away to collect the toll.
Menu development and regulatory clearance. The assay menu is the actual product. A platform with a hundred cleared assays is a different commercial object from a platform with fifteen, at almost identical manufacturing cost, which is why menu breadth and margin track each other across this industry.
Tender and distribution. In most of the world outside the United States the sale is a public tender, and the tender is decided on cost per reportable result rather than on instrument price. In China it is now a centralised volume-based procurement, which is a tender with the price ceiling set administratively before the bidding starts.
Laboratory and payer. The laboratory converts the reagent into a billable result and is paid by a health system or an insurer. The laboratory keeps the difference between the reagent price and the test price, which means every deflation in the reagent price is a transfer from the manufacturer to the laboratory - and every deflation in the test price is a transfer from the laboratory to the payer.
| Measure | 2025 | What it measures |
|---|---|---|
| QIAGEN, adjusted operating margin | 29.5% | The return on sample technology and a narrow, high-attach menu |
| Thermo Fisher Specialty Diagnostics, segment income margin | 26.9% (USD 1,256m on USD 4,676m) | The return on a deep, specialised IVD menu |
| QuidelOrtho, adjusted EBITDA margin | 22.0% (USD 597m on USD 2,730m) | The return on a mature, 84%-recurring franchise |
| bioMerieux, CEBIT margin | 17.9% (EUR 728m on EUR 4,070m) | The return on clinical microbiology and syndromic panels |
| Siemens Healthineers Diagnostics, adjusted EBIT margin | 7.7% (EUR 333m on EUR 4,347m) | The return on a broad, low-density installed base during restructuring |
| QuidelOrtho, adjusted gross margin | 47.4% | What the reagent itself earns before the cost of selling it |
The spread between 7.7% and 29.5% on businesses that all sell reagents into hospitals is the most important fact in this chapter, and manufacturing cost does not explain it. What explains it is density and menu depth. QIAGEN runs a narrow, high-value menu with a very high attach rate and earns 29.5%. Siemens runs a broad platform estate across a large number of hospital laboratories, carries the field service cost of all of them, and earned 5.3% in fiscal 2024 before its transformation programme took it to 7.7% in fiscal 2025 - a 240 basis point improvement delivered mainly by cost reduction, not by price.
The most important piece of value-chain mechanics in this market is a Chinese provincial document. Between 2023 and 2025 the Chinese healthcare security authorities moved in stages: a 25-province alliance for IVD reagents in 2023, a 28-province volume-based procurement covering tumour markers and thyroid function in 2024, and in 2025 the Anhui-led cardiac marker panel, the Gansu-led procurement of routine blood, stool and urine reagents - the first time routine laboratory products entered scope - and Jiangsu's inclusion of non-invasive prenatal genetic testing services, the first time a testing service rather than a reagent was procured this way. National and provincial alliance items across the country were expected to exceed 700 in 2025.
The Jiangxi biochemical reagent alliance published the outcome in January 2025: 154 manufacturers and 2,314 specifications awarded, at an average price reduction of 70%. The lowest winning bid in the alliance was RMB 0.03 per unit. Roche Diagnostics and Mindray both won lines at RMB 0.07.
That is the single most consequential number in this report, and its value chain consequence runs in one direction. A 70% cut in the reagent price does not cut the manufacturer's cost by 70%, so the margin on that line compresses almost to zero; the volume that the award confers is real, and the winner is the manufacturer with the lowest cost base. This is precisely why the domestic Chinese manufacturers gain share in a volume-based procurement and the multinationals do not: the multinational carries a global cost structure and a global price list, and the domestic manufacturer carries neither. In our interviews with procurement executives, the mechanism was described the same way repeatedly - the tender is not where the price is discovered, it is where the price is enforced.
Roche's 2025 diagnostics disclosure is the cleanest available map of where value sits inside a portfolio. Core Laboratory is the largest line at CHF 7.6 billion and it was flat for the year, with immunodiagnostics down 3% and clinical chemistry up 7%. Molecular Laboratory is a third of that size at CHF 2.5 billion and grew 4%. Pathology Laboratory is smaller still at CHF 1.7 billion and grew 14%, driven by companion diagnostics at +25% and advanced staining at +10%. Near Patient Care shrank, with blood glucose monitoring down 2% and the Liat point-of-care molecular line down 5%.
Ranked by growth rather than by size, that portfolio inverts: the smallest and most specialised businesses - pathology and companion diagnostics - grow fastest, and the largest commodity business is flat. Ranked by revenue, the commodity business is four and a half times the size of the specialised one. The margin in this market accrues to the manufacturer who holds the specimen and the report, not to the one who holds the reagent bottle, and pathology is the position that holds the report.
Two elements of the chain remain unquantifiable from disclosure and are named here rather than estimated: the cost of instrument service in geographies where placement density is low, which is carried inside the segment margin and never disclosed separately; and the cost of obsolescence when a platform is discontinued, which QIAGEN disclosed in 2025 as roughly USD 20 million of headwind from the NeuMoDx and Dialunox product exits. Both are real, both are larger in emerging markets, and neither appears in a gross margin.
" investment_activity_content: "This is a capital-light, cash-generative market that has spent the last three years consolidating and restructuring rather than building. The distinguishing feature of 2025 was not the size of the deals but what they were buying: installed base and menu, not technology.
| Participant | 2025 cash and margin measure | What it says |
|---|---|---|
| Siemens Healthineers Diagnostics | Adjusted EBIT EUR 333m, a 7.7% margin, from EUR 235m and 5.3% in fiscal 2024 | A transformation programme can add 240 basis points without a price increase |
| bioMerieux | CEBIT EUR 728m at 17.9% of sales, up 16% at constant exchange rates | Menu-led growth converts to margin |
| Thermo Fisher Specialty Diagnostics | Segment income USD 1,256m at 26.9% | The highest margin in the peer set on a specialised menu |
| QuidelOrtho | Adjusted EBITDA USD 597m at 22.0%, up 240 basis points; GAAP net loss USD 1.13bn | A USD 701m goodwill impairment is an accounting judgement about a past acquisition, not a 2025 trading result |
| QIAGEN | Adjusted operating margin 29.5%, up 80 basis points | Tariffs and currency absorbed without margin loss |
| Danaher Diagnostics | Roughly USD 1bn of sustainable incremental annual revenue attributed to the Cepheid base | Placement is the capital allocation decision that matters |
The pattern is consistent enough to state as a rule: in this market, margin comes from menu depth per placement, and cash comes from the density of the installed base. Siemens added 240 basis points of diagnostics margin by taking cost out of a broad estate. bioMerieux added margin by growing cartridges at 84% on a 110% larger installed base. QuidelOrtho held a 22% adjusted EBITDA margin while its revenue fell 2%, because 84% of that revenue was recurring.
The strategically informative moves in this market are about portfolio shape rather than about acquiring capability.
BD is separating rather than integrating. The proposed combination of BD's Biosciences and Diagnostic Solutions businesses with Waters is expected to close around the end of the first quarter of calendar 2026, after which BD's Life Sciences segment will be eliminated and BD will consist of four remaining segments. Diagnostic Solutions reported USD 1,838 million in fiscal 2025, down 0.4%. That is a company deciding that a USD 1.8 billion diagnostics unit is worth more inside a tools and instruments business than inside a medical products company.
Werfen has already completed the same logic in reverse. It divested its medical devices business in July 2024 and its 2025 figures reflect exclusively in vitro diagnostics activity - EUR 2,131 million of sales, EUR 473 million of EBITDA, EUR 190 million of research and development at 9% of sales. A pure-play IVD company at a 22% EBITDA margin is the cleanest read available on what this market's economics look like without a devices business attached.
QIAGEN bought menu and sample technology. It completed the acquisition of Parse in December 2025 while discontinuing NeuMoDx and Dialunox at a cost of roughly USD 20 million of 2025 revenue. Buying a menu and killing a platform in the same year is a statement about where the return is: in assays that run on an installed base, not in another box.
QuidelOrtho's impairment is the cautionary case. A USD 701 million goodwill write-down in the third quarter of 2025, on a business that still produced a 22% adjusted EBITDA margin, is a reminder that the return on an acquisition in this market is decided by the installed base you inherit and the menu you can put on it, and not by the price you paid for the revenue.
Capital intensity in in vitro diagnostics is moderate and falling, and the reason is that the instrument is not the investment. Analysers are placed, leased or sold near cost; the consumables are bought as used; the marginal cost of an additional test is dominated by reagents and labour rather than by capacity. What is expensive is the assay menu and the regulatory programme that clears it - a fixed cost paid before any revenue exists, and the real barrier to entry in molecular and in specialised chemistry.
That produces an unusual capital profile: an established platform business converts a high proportion of revenue into cash, and a business trying to enter a new discipline does not, whichever size it is. It also explains the direction of consolidation. Nobody in 2025 bought a technology that did not already have a menu and a placement. The scarcity in this market is not innovation and it has not been for a decade. It is the right to be on the bench.
For a strategic acquirer the implication is that an IVD asset should be underwritten on installed-base density and menu coverage rather than on growth rate. For an investor, the observable that matters is the direction of reagent price per reportable result in the two largest markets: if China keeps resetting it and the United States keeps paying for the test rather than the reagent, the revenue line and the margin line will keep diverging, and 5.74% will be a forecast about the former only.
" technology_innovation_content: "Four technology architectures do the work in in vitro diagnostics, and they are not generations of one another. They answer different questions, they are bought by different departments and they carry different economics - which is why this forecast grows at four different rates across them.
A high-throughput analyser that runs immunoassay and clinical chemistry on the same track, usually the analytics engine of a hospital laboratory performing thousands of tests a day. Abbott's Alinity, Roche's cobas, Siemens' Atellica and Beckman Coulter's DxC and Access are the reference platforms. The technology is mature and the competition is not about chemistry: it is about automation, track connectivity, sample handling and the number of assays that can be run without stopping the line. This is where 40% of the market sits and where growth is closest to health system budget growth, because the alternative to buying more reagent is simply running the analyser for another shift.
Single-use, sealed, room-temperature-stable PCR or isothermal cartridges that non-specialist staff can run. This is the architecture that has changed the shape of the market over the last five years, and the disclosure is explicit about why. Danaher reports that Cepheid has tripled its installed base since the beginning of the pandemic, to more than 60,000 instruments, with more than 30 FDA-cleared assays and more outside the United States, and that this base carries roughly USD 1 billion of sustainable incremental annual revenue. bioMerieux's SPOTFIRE - the small-footprint cartridge system - reached EUR 168 million of sales, up 84% in value and more than 100% in volume, with an installed base of 6,400 instruments, up 110%, while its larger BIOFIRE non-respiratory panels grew 10% to EUR 598 million with a net installed-base expansion of 1,800 units.
The economics of the cartridge are the reason it grows at 8.5% while the core laboratory grows at 4.5%. A cartridge test is priced per episode, it is not commoditised by a reagent tender, and it moves a test to a setting where no laboratory exists - an emergency department, a physician office, a field clinic. Our field programme found the same pattern in every market we covered: the cartridge is adopted not because it is more accurate but because it removes a transport leg between the patient and the answer.
A multiplex panel that tests one specimen for fifteen to twenty pathogens at once. Its clinical proposition is antimicrobial stewardship - a result in an hour changes whether a broad-spectrum antibiotic is started - and that proposition is why the panel survives price pressure that destroys a single-analyte test. bioMerieux's BIOFIRE franchise is the reference case, growing 10% in non-respiratory panels on an installed base that expanded by 1,800 instruments in a single year. The constraint is reimbursement rather than technology: a panel is paid for as one test or as several depending on the jurisdiction, and the difference determines whether the laboratory can afford to run it.
The most consequential new IVD category of this decade arrived in 2025, and it is not a cancer test. The US Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in the diagnosis of Alzheimer's disease: the Lumipulse G pTau217 and ss-Amyloid 1-42 Plasma Ratio, for adults aged 55 and over presenting with signs and symptoms of cognitive decline. In the clinical study supporting the clearance, 91.7% of individuals with a positive result had amyloid plaques confirmed by PET or cerebrospinal fluid, 97.3% of those with a negative result were confirmed negative, and fewer than 20% of the 499 patients tested received an indeterminate result. The agency was explicit that the test is not a screen and not a stand-alone diagnosis.
Read the implications rather than the assay. Until this clearance, confirming amyloid pathology required a PET scan or a lumbar puncture. A plasma ratio on an existing immunoassay platform turns the highest-volume unmet diagnostic question in neurology into a routine blood draw, on installed instruments, at a reagent price. It does not require a new platform, a new laboratory or a new sales force. That is the ideal shape of an IVD product, and it is the reason the immunoassay and clinical chemistry segment is forecast to keep growing at 4.5% rather than at the rate of GDP: the menu on the installed base is still getting better.
Every capability required by this forecast already exists and is cleared. Quantitative PCR runs on 60,000 cartridge systems. Syndromic panels are routine. Sequencing costs have fallen far enough that panel price is not the constraint on molecular demand. Digital pathology imagers are installed and reimbursed in a growing number of jurisdictions - Roche's advanced staining grew 10% and companion diagnostics 25% in 2025 on the strength of that shift.
What constrains the market is menu approval and reimbursement, and both are slow. An assay must be cleared or registered, then coded, then covered, then adopted - four gates that each take quarters rather than weeks. The technology risk in this market is therefore almost zero and the execution risk is high. The correct question about any new IVD technology is not whether it works. It is whether the laboratory can bill for it.
" market_risk_content: "The risks that decide this market are administrative rather than clinical. The assays work and the volume is growing. What can remove revenue is a procurement award, a tariff, a coverage policy or a price administration - and every one of those is decided by an institution rather than by a competitor.
Volume-based procurement moved from tumour markers and thyroid function in 2024 to cardiac markers and routine blood, stool and urine reagents in 2025. The Jiangxi biochemical alliance awarded 2,314 specifications at an average reduction of 70%. Routine haematology and urinalysis are the largest single block of this market's volume, and they entered scope for the first time in 2025.
The risk is not that the 2025 cut repeats. It is that the mechanism keeps extending - into immunochemistry, into microbiology, and now into testing services themselves, as Jiangsu did with non-invasive prenatal testing. Each extension resets a price that was previously negotiated. This is the single largest exposure in the forecast: if immunoassay and clinical chemistry grows at 2.5% rather than 4.5%, the 2033 market is USD 160.05 billion and the CAGR 5.04%.
Abbott's diagnostics division fell 4.5% organically in 2025 and would have grown 0.4% excluding COVID testing, because COVID sales fell from USD 176 million to USD 89 million in the fourth quarter alone. QuidelOrtho's respiratory revenue fell 20% to USD 402 million on lower COVID testing. Roche's point-of-care molecular line fell 5%. Every one of those is a comparator effect that will disappear, and every one of them depressed the base year. It is a risk to the reading of 2025 and an upside to the forecast, not a downside.
Siemens reported its fiscal 2025 margin against higher tariffs and cited them explicitly. Sysmex cut guidance from JPY 560 billion to JPY 535 billion citing US reciprocal tariffs and Chinese government procurement policy. QIAGEN absorbed tariffs and currency while still raising adjusted operating margin 80 basis points, which is the exception rather than the rule at smaller scale. A tariff on an instrument or a reagent is a cost that cannot be passed through in a tendered market, and it lands directly on the segment margin.
In a volume-based procurement the domestic manufacturer wins because it can survive a price the multinational cannot, and the multinational's correct response - declining to bid - is a decision to lose the account. Over eight years the compounding consequence is not a lower price but a permanently smaller addressable share in the largest volume geography. Our interviews with procurement executives in Asia described domestic-first lists and localisation scoring as ordinary features of a tender rather than as exceptions, and that is a structural change in who can sell, not a cyclical change in what they earn.
Every growth rate above volume growth in this model requires either new placements or a richer menu on the existing ones. A reagent annuity is a claim on an instrument that someone else can win back at the next tender cycle. The defence is the cost of switching, and that cost is falling as laboratories move to multi-vendor arrangements specifically so that they can re-tender without losing the platform. A market where the switching cost falls is a market where the annuity is worth less each year, and none of the participants discloses placement attrition in a way that would let a reader measure it.
The highest-growth discipline in this forecast is also the one most exposed to commoditisation. A cartridge PCR test is technically hard to differentiate and increasingly easy to manufacture. The 8.5% growth rate for molecular assumes that syndromic panels and sequencing-based assays continue to command a premium over single-analyte PCR, and the evidence for that in 2025 was mixed: bioMerieux's non-respiratory BIOFIRE panels grew 10% while Hologic's Aptima CT/GC and HPV revenue fell on lower average selling prices as volumes grew with larger laboratory customers. Volume up and price down is not a premium market.
Demand. Test volume is a function of population, age structure, clinical guidelines and the number of assays on the menu, and none of those is contracting. The cartridge installed base tripled in five years. The first blood-based Alzheimer's test was cleared in 2025 and turns a PET scan into a reagent. Digital pathology is being reimbursed. The volume side of this market is not in question, which is precisely why the forecast is a price forecast in disguise.
Overall market risk assessment: moderate. The growth forecast is well supported by installed-base and menu evidence, and the demand base is the most durable in healthcare. The revenue line is exposed to an administered price in the largest volume geography, to tariffs on a tendered product, and to a switching cost that is falling. Each of those is a policy variable, and policy variables move in both directions.
" regulatory_landscape_content: "In vitro diagnostics is regulated twice: once as a device before it can be sold, and once as a price after it can be. The first gate is a registration and the second is a procurement, and in most of the world the second matters more to revenue.
European Union. Regulation (EU) 2017/746 on in vitro diagnostic medical devices replaced the previous directive and reclassified a large part of the assay population upwards, requiring notified body involvement where self-certification was previously sufficient. The practical consequences for this market are a longer time to market and a higher cost per assay, which structurally favours manufacturers with a large menu already placed and disadvantages the smaller manufacturer trying to add one assay.
United States. A device requires clearance or approval - 510(k), De Novo or premarket approval - unless it is a laboratory-developed test performed in a laboratory certified under CLIA and accredited by the College of American Pathologists. That exemption was contested: a rule issued in May 2024 that would have phased laboratory-developed tests into device regulation was vacated in March 2025, and the agency reverted to its pre-2024 framework in September 2025. The distinction matters commercially, because a cleared device is a product a hospital buys and a laboratory-developed test is a service a laboratory sells - and only one of them is inside this report's perimeter.
China. Registration through the National Medical Products Administration is the entry gate, and since 2023 centralised volume-based procurement has been the price gate. The sequencing is what matters: the procurement began with tumour markers and thyroid function across 28 provinces in 2024, moved to cardiac markers under Anhui's leadership and to routine blood, stool and urine reagents under Gansu's in 2025, and extended to a testing service for the first time when Jiangsu's non-invasive prenatal testing award took effect on 1 January 2025. Medical insurance price governance runs alongside it.
Rest of world. WHO prequalification governs procurement by multilateral buyers, and the International Medical Device Regulators Forum framework has largely harmonised classification. The significance for this market is that an assay cleared in one jurisdiction is rarely sellable everywhere without a further registration, which is why the multi-regional manufacturer carries an advantage that is administrative rather than scientific.
The price is set by a buyer, not by a seller. The Jiangxi biochemical alliance awarded 2,314 specifications at an average price reduction of 70%. A manufacturer cannot decline to participate without leaving the province, and cannot participate without accepting the price. This is the defining regulatory feature of the largest growth geography in the world and it is not a device regulation at all.
Reimbursement of the test is separate from registration of the test. A cartridge panel can be cleared in a quarter and remain unbillable for years. The gates that decide whether a laboratory can afford to run an approved assay - a code, a payment rate, a coverage policy - sit with a different institution from the one that cleared it, and they move on a different clock.
Industrial policy is now a procurement criterion. Localisation requirements in China, tariffs affecting instrument movement into the United States, and domestic-preference rules in several emerging markets all change the relative cost of an imported reagent against a locally manufactured one. Sysmex cited US reciprocal tariffs and Chinese government procurement policy in cutting its fiscal 2025 guidance from JPY 560 billion to JPY 535 billion. Siemens cited tariffs when reporting its fiscal 2025 margin. These are not regulatory hurdles in the traditional sense, and they move share faster than any registration decision does.
The regulatory environment does not threaten the 5.74%. It shapes who captures it. A stricter device regime raises the cost of adding an assay, which protects the installed base of a large-menu manufacturer. A volume-based procurement lowers the price of a reagent, which transfers value from the manufacturer to the laboratory and favours the lowest-cost producer. The two forces push in opposite directions on margin and in the same direction on consolidation: in both cases, scale wins.
" faq_question_1: "How large is the global in vitro diagnostics market?" faq_answer_1: "USD 108.0 billion in 2025, forecast to reach USD 168.8 billion by 2033. That is a compound annual growth rate of 5.74%, a multiple of 1.56x, and USD 60.8 billion of incremental value across the eight-year window. The 2025 figure is a bottom-up construction from twelve attributed revenue pools worth USD 61.5 billion plus a stated residual of USD 46.5 billion, not an inherited headline number." faq_question_2: "Why did the IVD market grow only about 1% in 2025 if the forecast is 5.74%?" faq_answer_2: "Because 2025 contained a one-time price reset in China, not a fall in test volume. Roche's China diagnostics sales fell 24% and its division grew 7% at constant exchange rates excluding China. Siemens, bioMerieux, Werfen and Sysmex all attribute part of their weakness to Chinese centralised procurement and government purchasing. A price administration resets the level once and does not compound, so a base year that contains it is artificially low. Volume growth was intact throughout: Abbott's Core Laboratory business grew 2.1% organically in the same year its diagnostics division fell 4.5%." faq_question_3: "What is inside the perimeter of this report and what is excluded?" faq_answer_3: "Inside: reagents, kits, controls, calibrators and consumables sold for human clinical diagnostic testing; the instruments and software placed in clinical, hospital and reference laboratories; and the disciplines of immunoassay and clinical chemistry, molecular diagnostics, point-of-care and rapid testing, hematology, hemostasis, urinalysis, microbiology and blood culture, blood banking, and IVD-attributable histopathology and digital pathology. Excluded, and stated in the scope table: laboratory services revenue, research-use-only reagents, life science instruments and biopharma services, veterinary, food and environmental testing, industrial and pharma quality control, and medical imaging." faq_question_4: "Who are the largest participants in in vitro diagnostics?" faq_answer_4: "On the attributed revenue in this report: Roche Diagnostics at USD 15,924 million, Danaher Diagnostics at USD 9,941 million, Abbott Diagnostics at USD 8,937 million, Siemens Healthineers Diagnostics at USD 4,912 million and Thermo Fisher Specialty Diagnostics at USD 4,676 million. Those five account for USD 44,390 million, or 41.1% of the base year. The twelve named participants account for 57.0%. The remaining 43.0% is a long tail of Chinese, Japanese, Korean, Indian and regional reagent manufacturers serving their own health systems." global_schema: organization: "@id": MIWS-root#organization "@type": Organization url: "https://www.pheonixresearch.com/" name: Pheonix Research website: "@id": MIWS-root "@type": WebSite url: "https://www.pheonixresearch.com/" name: Pheonix Research api: "@id": MIWS-root#api "@type": WebAPI url: "https://www.pheonixresearch.com/" graph: node_id: MIMR-node_0273345 graph_node_endpoint: "https://graph.pheonixresearch.com/api/v1/query/live/node/MIMR-node_0273345" graph_snapshot: "https://graph.pheonixresearch.com/api/v1/read/live/graph" graph_exclusions: "https://graph.pheonixresearch.com/api/v1/read/live/exclusions" graph_meta: "https://graph.pheonixresearch.com/api/v1/read/live/meta" graph_bundle: "https://graph.pheonixresearch.com/api/v1/read/live/bundle" discovery: discovery_json: "https://www.pheonixresearch.com/.well-known/pheonix-discovery.json" llms_txt: "https://www.pheonixresearch.com/llms.txt" sitemap: "https://www.pheonixresearch.com/sitemap.xml" --- # Global In Vitro Diagnostics (IVD) Market Report, Size, Share and Forecast 2026-2033 - **Market Size (Base Year):** USD 108 Billion - **Forecast Value:** USD 168.8 Billion - **CAGR:** 5.74% - **Forecast Period:** 2026 - 2033 ## Market Report ## Market Forecast Snapshot, 2025-2033 | Indicator | | Value | | Market value, 2025 | | USD 108.0 billion | | Market value, 2033 | | USD 168.8 billion | | Compound annual growth rate, 2025-2033 | | 5.74% | | Growth multiple | | 1.56x | | Incremental value created, 2025-2033 | | USD 60.8 billion | | Growth rate in the first forecast year, implied by the segment build | | 5.65% | | Aggregate 2025 growth of the twelve largest participants, on their own organic measures | | 1.2% | | Share of the base held by the twelve largest participants | | 57.0% (USD 61.5 billion) | | Currency and basis | | USD, nominal, 2025 average exchange rates (EUR 1.00 = USD 1.13; CHF 1.00 = USD 1.15; JPY 148 = USD 1.00) | | Forecast horizon | | 2026-2033 | The global in vitro diagnostics market was worth **USD 108.0 billion in 2025** and is forecast to reach **USD 168.8 billion by 2033**, a compound annual growth rate of **5.74%**. That is 1.56x on the base year, or USD 60.8 billion of incremental value across eight years. ## The thesis: the market grew 1.2% last year, and the forecast is 5.74% In 2025 the twelve largest in vitro diagnostics companies in the world sold **USD 61.5 billion** of diagnostic product between them. Weighted by that revenue and measured on each company's own organic or constant-currency basis, they grew **1.2%**. Read the individual lines and the picture is not ambiguous. Abbott's diagnostics division reported USD 8,937 million, down 4.5% organically. Siemens Healthineers' diagnostics segment turned over EUR 4,347 million, up 0.4% on a comparable basis. BD's Diagnostic Solutions unit did USD 1,838 million, down 0.7% at constant exchange rates. QuidelOrtho reported USD 2,730 million, down 2.1% in constant currency. Roche's diagnostics division reached CHF 13,847 million, up 2% at constant exchange rates and down 3% in Swiss francs. The fastest of the majors was bioMerieux at 6.2% organic, and it is a EUR 4.1 billion business. This report forecasts 5.74% a year for eight years. The gap between 1.2% and 5.74% is the entire argument, and it has a name: **China**. 2025 was the year the administered price of a Chinese reagent reset, and the disclosures say so in unusually plain language. Roche's diagnostic sales in China fell **24%** for the year, taking Asia-Pacific down 12% while every other region grew at a mid-single-to-low-double-digit rate; the same division grew **7% at constant exchange rates excluding China**. Siemens named centralised volume-based public procurement as the specific cause of a low-double-digit decline in its China diagnostics revenue. bioMerieux grew microbiology 4% including China and **6.3% excluding it**, and reported a mid-single-digit organic decline in China in the fourth quarter. Werfen, which became a pure IVD company after divesting its medical devices business in July 2024, grew 3.3% organically and wrote the mechanism into its own release: the industry faced a widespread adjustment within the in vitro diagnostics market in China, and excluding Asia its organic growth was **6%**. Sysmex guided fiscal 2025 down from a JPY 560 billion plan to JPY 535 billion, citing Chinese government procurement policy and US tariffs. Hologic reported lower cytology volume in China. That is six independent companies describing the same event in the same year. A price administration is not a demand event, and it does not compound. It is a one-time reset of the price level, and a base year that contains it is artificially low. The 5.74% forecast is not a bet that China recovers. It is what happens to a five-year growth rate when the deflating base laps. The second half of the argument is that volume never stopped. Abbott's Core Laboratory business grew 2.1% organically to USD 5,360 million while its diagnostics division fell 4.5%, because the division's decline was almost entirely the COVID testing tail: COVID testing sales were USD 89 million in the fourth quarter against USD 176 million a year earlier, and the unwind cost 4.9 percentage points of full-year diagnostics organic growth. Strip COVID out and Abbott's diagnostics business grew 0.4%. Roche's clinical chemistry grew 7% while immunoassay fell 3%. Hologic's molecular business grew on BV/CV adoption and a severe flu season while its SARS-CoV-2 assays declined. In every case the routine testing volume is intact and the reported number is being moved by price, by a winding-down product line, or by a comparator. ## The 2025 disclosures this report is built on | Participant | | 2025 IVD-attributable revenue, USD m | | Reported growth | | The line that matters | | Roche Diagnostics | | 15,924 (CHF 13,847m) | | +2% CER, -3% CHF | | Ex-China +7% CER; China -24%; Core Lab CHF 7.6bn flat | | Danaher Diagnostics | | 9,941 | | +1.6% | | Cepheid installed base above 60,000 instruments, tripled since 2020 | | Abbott Diagnostics | | 8,937 | | -4.3% reported, -4.5% organic | | Core Lab USD 5,360m up 2.1%; Rapid Diagnostics down 18.0% | | Siemens Healthineers Diagnostics | | 4,912 (EUR 4,347m) | | +0.4% comparable | | Adjusted EBIT margin 7.7%, up from 5.3% | | Thermo Fisher Specialty Diagnostics | | 4,676 | | +3.6% reported, +3% organic | | Segment income USD 1,256m, a 26.9% margin | | bioMerieux (clinical) | | 3,679 (EUR 3,256m) | | +6.2% organic | | CEBIT margin 17.9%; SPOTFIRE to EUR 168m, +84% | | Sysmex (clinical) | | 3,399 (JPY 503bn) | | +5.2% on guidance | | Guidance cut from JPY 560bn on China and tariffs | | QuidelOrtho | | 2,730 | | -1.9% | | Recurring revenue 84% of the total; respiratory -20% | | Werfen | | 2,408 (EUR 2,131m) | | +3.3% organic | | Ex-Asia +6%; EBITDA EUR 473m; pure IVD since July 2024 | | BD Diagnostic Solutions | | 1,838 | | -0.4% reported, -0.7% FXN | | BD MAX IVD double-digit growth; blood culture utilisation above 85% of historical US levels | | Hologic Diagnostics | | 1,827 | | +2.5% | | BV/CV and Fusion respiratory volumes up; Aptima ASPs down | | QIAGEN (clinical) | | 1,254 (USD 2,090m group) | | +5% CER | | Adjusted operating margin 29.5%; NeuMoDx and Dialunox discontinued | | **Named pool** | | **61,525** | | **+1.2% weighted organic** | | **57.0% of the 2025 base** | ## Three findings that carry the forecast **One: the annuity is the business, and the instrument is the toll booth.** QuidelOrtho reports that 84% of its revenue is recurring, which is to say assays, reagents, consumables and service rather than instruments. Abbott's Core Laboratory line, at USD 5,360 million, is four times its Molecular line and six times its Point of Care line, and it is a reagent annuity attached to Alinity placements. Siemens states the model explicitly in its annual report: diagnostics generates profits mainly from long-term contracts that include an initial instrument placement followed by ongoing reagent sales, which result in a predictable and resilient revenue stream. Every forecast in this market is therefore a forecast about consumed reagents, and reagent consumption is a function of test volume, not of hospital capital budgets. **Two: margin is set by menu breadth and installed-base density, not by assay performance.** Siemens runs EUR 4.35 billion of diagnostics revenue at a 7.7% adjusted EBIT margin. bioMerieux runs EUR 4.07 billion at a 17.9% CEBIT margin. Thermo Fisher's Specialty Diagnostics segment converts USD 4,676 million into USD 1,256 million of segment income, a 26.9% margin. These are similar products sold into the same laboratories at wildly different profitability, and the difference is what is on the menu and how densely it is placed. A platform with a shallow menu carries the same service cost as a platform with a deep one, and earns less per placement. **Three: volume is growing and price is not.** Three companies disclosed enough in 2025 to separate the two. Hologic reported Aptima CT/GC and HPV revenue lower on slightly lower average selling prices as volumes increased with larger laboratory customers, which is the clearest statement in the dataset that large laboratories are converting share into price. Roche reported immunodiagnostics down 3% and clinical chemistry up 7% inside a flat Core Lab, a mix shift rather than a volume collapse. Abbott reported Core Lab organic growth of 2.1% against a China volume-based procurement headwind. Every one of those is a price line, and every one of them is administered rather than negotiated in a competitive market. ## What is inside the perimeter, and why the level is where it is The single largest source of disagreement between published estimates for this market is not the forecast. It is the boundary, and specifically three questions: whether laboratory services are inside, whether research-use-only reagents are inside, and whether the vendors' non-clinical businesses are inside. | Inside the perimeter | | Outside the perimeter | | Reagents, kits, controls, calibrators and consumables sold for human clinical diagnostic testing | | Revenue earned by laboratories for performing tests - that is a services market, covered separately on this site | | Instruments, analysers and associated software placed in clinical laboratories, hospitals, reference laboratories and physician offices | | Research-use-only reagents, life science instruments and biopharma services | | Immunoassay and clinical chemistry, molecular diagnostics, point-of-care and rapid tests, hematology, hemostasis, urinalysis, microbiology and blood culture, blood banking, and IVD-attributable histopathology and digital pathology | | Veterinary diagnostics, food and environmental testing, industrial and pharma quality control, and forensic testing | | Service and support revenue attaching to a placed clinical instrument | | Medical imaging, radiotherapy and interventional devices, even where sold by an IVD company | Two boundary decisions change the level materially and are stated here rather than buried. First, **industrial and pharma quality control is excluded**, which removes roughly 20% of bioMerieux's reported sales and a meaningful slice of Thermo Fisher's microbiology franchise; the figures in this report attribute only the clinical portion. Second, **laboratory services are excluded**, which is why the USD 108.0 billion figure is smaller than the total spend on diagnostic testing: the reagent is a fraction of the price of a reportable result, and the laboratory that turns one into the other keeps the difference. A figure of USD 108 billion and a figure of USD 160 billion can both describe diagnostics honestly if one is the reagent and instrument market and the other is the testing market. This report fixes the boundary above and builds to it. ## How the 2025 base was constructed The base is built bottom-up from disclosed revenue and contains a stated residual. It is not an average of published estimates and no published aggregate was used to set the level. | Component | | 2025, USD m | | Share of base | | Twelve named participants, IVD-attributable lines only | | 61,525 | | 56.97% | | Stated residual: Chinese and regional reagent manufacturers, hospital in-house and consolidated laboratory networks, unlisted specialists, blood banking and immunohematology, and named vendors' IVD lines not separately disclosed | | 46,475 | | 43.03% | | **Total, 2025** | | **108,000** | | **100%** | A 43% residual is large, and it is the honest shape of this market. In vitro diagnostics is not a concentrated industry at the point of manufacture. The twelve largest companies account for 57% of value because they dominate immunoassay, hematology and molecular platforms in the high-income markets. The other 43% is thousands of reagent manufacturers, of which the Chinese domestic industry is the largest single block, plus the Japanese, Korean, Indian, Brazilian and Turkish suppliers who serve their own health systems at prices the multinationals do not reach. That tail is where the volume growth is fastest and where the price deflation is most severe, which is why the residual is assumed to grow 3.1% in 2025 against 1.2% for the named pool, and why the two are modelled separately rather than averaged. Three construction choices should be declared. Revenue is attributed to the calendar year in which it was earned, so Siemens Healthineers and BD appear on their fiscal years ended 30 September 2025. Non-USD revenue is translated at the average 2025 rates in the snapshot table rather than at spot, which affects the level and not the growth rate. And where a company does not disclose an IVD line separately, the attribution share is stated in the disclosure table above rather than estimated silently in the total. ## The segment build, and why the CAGR is higher than the first year | Test discipline | | 2025, USD m | | Share | | Growth 2026-2033 | | 2033, USD m | | 2033 share | | Immunoassay and clinical chemistry | | 43,000 | | 39.81% | | 4.5% | | 61,150 | | 36.23% | | Molecular diagnostics, including syndromic panels and sequencing | | 22,000 | | 20.37% | | 8.5% | | 42,253 | | 25.03% | | Point-of-care and rapid diagnostics | | 17,500 | | 16.20% | | 6.0% | | 27,892 | | 16.52% | | Hematology, hemostasis and urinalysis | | 12,500 | | 11.57% | | 4.0% | | 17,107 | | 10.13% | | Microbiology and blood banking | | 8,000 | | 7.41% | | 5.0% | | 11,820 | | 7.00% | | Histopathology and digital pathology, IVD-attributable | | 5,000 | | 4.63% | | 7.0% | | 8,591 | | 5.09% | | **Total** | | **108,000** | | **100%** | | **5.65% in 2026** | | **168,814** | | **100%** | The segment build produces **5.65%** growth in the first forecast year. The eight-year compound rate is **5.74%**, and the nine basis point gap is arithmetic rather than error: the faster disciplines compound up in weight. Molecular diagnostics is 20.37% of the base today and 25.03% of it in 2033, so a market growing 5.65% in 2026 arrives at 5.74% compounded. A reader who checks the first-year rate against the headline will find a gap, and the gap is the mix effect. The four-point spread between immunoassay at 4.5% and molecular at 8.5% is the whole shape of the forecast. Immunoassay and clinical chemistry is 40% of the market growing at roughly the rate of health system budgets, and it carries the China deflation because that is where the volume-based procurement has bitten hardest - first tumour markers and thyroid function across 28 provinces in 2024, then cardiac markers, then routine blood, stool and urine reagents. Molecular is smaller, faster and less exposed to a reagent tender, because a syndromic panel is bought by a clinician who needs an answer today rather than by a procurement office comparing unit prices. Two companion analyses work through the findings this growth rate depends on. [The Administered Price Is the Real Forecast Variable](https://www.pheonixresearch.com/healthcare/diagnostics/article/the-administered-price-is-the-real-forecast-variable/) separates the volume line from the price line across every participant that discloses both, and shows why a 2% growth rate in a year with intact test volume is a price statement rather than a demand statement. [Coverage Is the Product, and the Panel Is the Overhead](https://www.pheonixresearch.com/healthcare/diagnostics/article/coverage-is-the-product-and-the-panel-is-the-overhead/) reads the same participants' margins against the breadth of their menus and finds that the platform with the deepest menu earns the least per placement. Three further analyses work through the numbers this forecast depends on. [China's Price Cut Is Worth Half a Point of the IVD Forecast, Not Four](https://www.pheonixresearch.com/healthcare/diagnostics/article/chinas-price-cut-is-worth-half-a-point-of-the-ivd-forecast-not-four/) puts a value on the deflationary base year and finds it worth 0.52 points of the compound rate rather than four, which relocates the forecast's risk from the administered price to the molecular discipline. [Two Diagnostics Businesses, the Same Operating Profit, a Quarter of the Revenue](https://www.pheonixresearch.com/healthcare/diagnostics/article/two-diagnostics-businesses-the-same-operating-profit-a-quarter-of-the-revenue/) sets the disclosed margins side by side and shows that a franchise carrying 3.92 times the revenue can earn the same operating profit as a narrower one. [The 43 Per Cent of the IVD Market That Files No Accounts](https://www.pheonixresearch.com/healthcare/diagnostics/article/the-43-per-cent-of-the-ivd-market-that-files-no-accounts/) sets out exactly what the stated residual contains, and why the block with no audited line is the block that sets the price the rest of the market transacts at. Global in vitro diagnostics market size, 2025-2033 (USD billion). Annual pathway implied by the stated 2025 base and 5.74% CAGR. ## What would change the number - If molecular diagnostics grows at 6.5% rather than 8.5%: the 2033 market falls to USD 162.97 billion and the CAGR to 5.28%. This is the largest single sensitivity in the model, because molecular is the only discipline carrying a growth rate more than one point above the market. - If immunoassay and clinical chemistry grows at 2.5% rather than 4.5%: the 2033 market falls to USD 160.05 billion and the CAGR to 5.04%. This is what a second wave of volume-based procurement across immunoassay looks like, and it is the most likely way for this forecast to be wrong. - If the Chinese adjustment reverses rather than laps: the base year is understated, and the eight-year CAGR rises rather than falls, because 2033 is unaffected while 2025 moves down. - If installed-base placements stall: a reagent annuity cannot outgrow its instrument base. Every percentage point of the forecast above volume growth requires either more placements or a richer menu on the existing ones. The 5.74% figure is a revenue forecast. It is not a returns forecast, and the fact that a market of this size compounds at 5.74% while its leaders convert 40% of the market into 1.2% of growth is the subject of the competitive and value chain chapters that follow. Global in vitro diagnostics market, 2025-2033: USD 108.0bn to USD 168.8bn at a 5.74% CAGR. ## Sources This report is built from primary corporate and regulatory disclosure. Principal documents: Roche Finance Report and Full-Year Results 2025 presentation (29 January 2026); Abbott Laboratories Form 10-K for the year ended 31 December 2025 and fourth-quarter 2025 earnings release; Danaher Corporation Form 10-K for the year ended 31 December 2025 and fourth-quarter 2025 results; Siemens Healthineers Quarterly Statement Q4 fiscal 2025 and Annual Report 2025 (5 November 2025); Thermo Fisher Scientific fourth-quarter and full-year 2025 results (29 January 2026); bioMerieux 2025 financial results and Universal Registration Document (27 February 2026); QIAGEN fourth-quarter and full-year 2025 results (4 February 2026); Sysmex Report 2025 and business overview; BD fourth-quarter and full-year fiscal 2025 results and Form 10-K (6 November 2025); QuidelOrtho fourth-quarter and full-year 2025 results (11 February 2026); Werfen 2025 fiscal year results (9 April 2026); Hologic Form 10-K for the fiscal year ended 27 September 2025; US Food and Drug Administration, FDA Clears First Blood Test Used in Diagnosing Alzheimer's Disease, clearance of the Lumipulse G pTau217 and ss-Amyloid 1-42 Plasma Ratio. Chinese procurement mechanics are drawn from provincial healthcare security administration award notices for the Jiangxi biochemical reagent alliance and the Anhui-led immunoassay alliance, and from provincial procurement announcements for Gansu and Jiangsu. No third-party market research estimate has been used at any point in the construction of this forecast. **Discipline reports in this cluster:** [Global Clinical Chemistry and Urinalysis Market, 2026-2033](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-clinical-chemistry-and-urinalysis-market/) — USD 16.8 billion in 2025, 15.56% of this base and 13.32% of the 2033 base, and the discipline in which the price of every routine test is actually set. It sits alongside the immunoassay report; taken together the two account for USD 43.2 billion of the USD 108.0 billion base, or 40.0% of it, and they reconcile to the combined immunoassay and clinical chemistry line in the 2033 discipline split. ## Discipline reports in this cluster The related panel on this page is capped at ten reports, so the three discipline-level reports built underneath this hub are listed here rather than only in the sidebar. Together they are **USD 50.82 billion of the USD 108.0 billion base — 47.06%** of in vitro diagnostics value in 2025. - Global Immunoassay Market — USD 26.4 billion in 2025, 4.90% CAGR, 24.44% of IVD value. The volume grew and the revenue did not. - Global Clinical Chemistry and Urinalysis Market — USD 16.8 billion in 2025, 3.71% CAGR, 15.56% of IVD value. More results, less money each. - Global Haematology and Coagulation Diagnostics Market — USD 7.62 billion in 2025, 4.25% CAGR, 7.06% of IVD value. Two monopolies, one tender. The three are built to a common method so that they can be read against each other: bottom-up attribution from disclosed vendor revenue, a stated residual rather than an implied one, volume and value separated so that a price effect is not mistaken for a demand effect, and the administered price document identified by name. Their attributed coverage is **66.6%, 48.9% and 87.28%** respectively — and that ordering is the argument. The discipline that attributes best is the one that is easiest to tender, because concentration is what makes a price visible to a procurement authority. ### Cross-cutting: the reagent and consumable layer One report in this cluster cuts across the disciplines rather than sitting beside them. [Global IVD Reagents and Consumables](https://www.pheonixresearch.com/healthcare/diagnostics/market-report/global-ivd-reagents-and-consumables-market/) measures the USD 78.4 billion consumable layer — 72.59% of this base — across nine product classes, and it is additive with an instrument-and-service layer of USD 29.6 billion rather than with the discipline reports, each of which includes its own analysers. Its central finding is that the razor-and-blade ratio is a contract term rather than an industry constant: Sysmex books 61.58% of net sales as reagents, bioMérieux 83.38%, and the 21.8-point spread is the difference between selling and renting the analyser. Its second finding is that the reagent is the only part of the system a procurement authority can specify — which is why Anhui's 28-province alliance cut tumour-marker and thyroid reagents 52.6% on average, and why Snibe's domestic reagent revenue fell 13.77% while its domestic instrument revenue rose 6.88% in the same year. ## Table of Contents Table of Contents Market Forecast Snapshot, 2025-2033 The thesis: the market grew 1.2% last year, and the forecast is 5.74% The 2025 disclosures this report is built on Three findings that carry the forecast What is inside the perimeter, and why the level is where it is How the 2025 base was constructed The segment build, and why the CAGR is higher than the first year Competitive Landscape Value Chain and Margin Structure Technology Insight: The Menu, the Cartridge and the Blood Test Investment and Capital Formation Market Risk Assessment Regulatory and Policy Environment ## Competitive Landscape Competitive Landscape This market has twelve participants of tier-one scale and no concentration at the level of the technology. Every one of the twelve can measure an analyte. What is concentrated is the installed base, and the installed base is what decides who earns the annuity that follows. Two layers that share a market and little else Platform and reagent majors place instruments and sell the consumables that run on them: Roche, Danaher, Abbott, Siemens Healthineers, Thermo Fisher, bioMerieux, Sysmex, Werfen, BD, Hologic, QIAGEN and QuidelOrtho. Their costs are manufacturing, instrument placement at or below cost, field service and tender participation. Their revenue is a price per reagent and per test, and it recurs for as long as the instrument stays installed. The long tail is the other 43% of the market: Chinese domestic manufacturers, Japanese and Korean specialists, Indian and Brazilian suppliers, and the smaller European houses. Their cost base is a fraction of the multinationals’, they compete almost entirely on price, and they win exactly where a procurement office sets the price in advance. The Jiangxi biochemical alliance, in which 154 manufacturers won 2,314 specifications at an average cut of 70%, is the clearest illustration available of how that layer takes share: not by out-innovating the majors, but by being able to survive a price the majors cannot. The size ranking is not the growth ranking Participant Attributed 2025, USD m Share of base Reported growth Roche Diagnostics 15,924 14.7% +2% CER, -3% CHF Danaher Diagnostics 9,941 9.2% +1.6% Abbott Diagnostics 8,937 8.3% -4.5% organic Siemens Healthineers Diagnostics 4,912 4.5% +0.4% comparable Thermo Fisher Specialty Diagnostics 4,676 4.3% +3% organic bioMerieux (clinical) 3,679 3.4% +6.2% organic Sysmex (clinical) 3,399 3.1% +5.2% on guidance QuidelOrtho 2,730 2.5% -1.9% Werfen 2,408 2.2% +3.3% organic BD Diagnostic Solutions 1,838 1.7% -0.7% FXN Hologic Diagnostics 1,827 1.7% +2.5% QIAGEN (clinical) 1,254 1.2% +5% CER Top five 44,390 41.1% – Top twelve 61,525 57.0% +1.2% weighted The largest participant is among the slowest and the seventh-largest is the fastest. That is not a coincidence and it is not a comment on competence. Roche’s 14.7% share is built on a core laboratory franchise that was flat for the year; bioMerieux’s 3.4% share is built on syndromic cartridges growing at double digits. The first is a mature annuity defended on price, the second is a growing annuity defended on menu. Why the largest participant is the most exposed and the least fragile Roche is simultaneously the largest participant in this market and the one with the most visible policy exposure. Its diagnostics division grew 2% at constant exchange rates and fell 3% in Swiss francs, and the whole of the shortfall is one geography: China down 24% and Asia-Pacific down 12%, against mid-single-to-low-double-digit growth in every other region, and +7% for the division excluding China. Immunodiagnostics fell 3% inside a flat Core Laboratory, which is where a reagent price cut lands first. The same disclosure also shows the defence. Molecular Laboratory grew 4% on blood screening, Pathology Laboratory grew 14% behind companion diagnostics at +25% and advanced staining at +10%, and clinical chemistry grew 7% inside a flat Core Lab. A franchise that broad does not lose a geography, it re-mixes around it. The fragility is that the re-mix is slower than the price cut. The Danaher position: the installed base as a moat Danaher is the most instructive competitor in the market because it has converted instrument placement into a structural position. Cepheid’s installed base is above 60,000 instruments, tripled since 2020, carrying more than 30 FDA-cleared assays and roughly USD 1 billion of sustainable incremental annual revenue on the company’s own framing. Sexual health assays grew approximately 20% in the third quarter of fiscal 2025. Alongside it, Radiometer in blood gas and Leica Biosystems in anatomic pathology are each separately described as more than USD 1 billion businesses, and Leica is the vehicle for digital pathology. That is three different annuity structures – a cartridge base, a blood gas base and a pathology base – in one segment, and it is why Danaher’s diagnostics revenue grew 1.6% in a year when the market grew about 2%. The moat is not the assay. It is the fact that removing a Cepheid from a molecular laboratory requires someone to decide to do it. What our field programme found about how share actually moves In 46 depth interviews across eleven markets, the mechanism of share change was described consistently and it was not clinical superiority. It was contract structure. Laboratories are moving from single-vendor commitments towards multi-vendor arrangements precisely so that a reagent price can be re-tendered without losing the platform, and the buying metric quoted most often was cost per reportable result rather than price per test or instrument price. That single shift explains why menu breadth is worth more than assay performance: a laboratory that buys on cost per reportable result is buying throughput, uptime and menu coverage, and it will pay a premium for a platform that never stops. In vitro diagnostics by test discipline, 2033 (USD billion). Molecular diagnostics rises to 25.0% of the market from 20.4% in 2025. - **Structure:** consolidated at the top, fragmented at the tail - **Tier 1 Players:** 12 - **Intensity:** High ## Value Chain Value Chain and Margin Structure The value chain in in vitro diagnostics runs from a reagent lot to a reportable result, and the margin is not distributed where the manufacturing is. Almost every percentage point of profit in this market is earned in the annuity that follows an instrument placement. The chain, in order Reagent manufacturing. Antibodies, enzymes, oligonucleotides, buffers and the plastics they are carried in. Gross margins here are high and reasonably stable, but the manufacturing cost is a small fraction of what the laboratory eventually pays, because the antibody is not the product – the validated performance on a specific analyser is. Instrument placement. The analyser is sold near cost, leased, or placed under a reagent commitment. Siemens states the model in its own annual report: long-term contracts that begin with an instrument placement and continue with reagent sales, generating a predictable revenue stream. The instrument is a toll booth that is given away to collect the toll. Menu development and regulatory clearance. The assay menu is the actual product. A platform with a hundred cleared assays is a different commercial object from a platform with fifteen, at almost identical manufacturing cost, which is why menu breadth and margin track each other across this industry. Tender and distribution. In most of the world outside the United States the sale is a public tender, and the tender is decided on cost per reportable result rather than on instrument price. In China it is now a centralised volume-based procurement, which is a tender with the price ceiling set administratively before the bidding starts. Laboratory and payer. The laboratory converts the reagent into a billable result and is paid by a health system or an insurer. The laboratory keeps the difference between the reagent price and the test price, which means every deflation in the reagent price is a transfer from the manufacturer to the laboratory – and every deflation in the test price is a transfer from the laboratory to the payer. Margins diverge by more than twenty points on similar products Measure 2025 What it measures QIAGEN, adjusted operating margin 29.5% The return on sample technology and a narrow, high-attach menu Thermo Fisher Specialty Diagnostics, segment income margin 26.9% (USD 1,256m on USD 4,676m) The return on a deep, specialised IVD menu QuidelOrtho, adjusted EBITDA margin 22.0% (USD 597m on USD 2,730m) The return on a mature, 84%-recurring franchise bioMerieux, CEBIT margin 17.9% (EUR 728m on EUR 4,070m) The return on clinical microbiology and syndromic panels Siemens Healthineers Diagnostics, adjusted EBIT margin 7.7% (EUR 333m on EUR 4,347m) The return on a broad, low-density installed base during restructuring QuidelOrtho, adjusted gross margin 47.4% What the reagent itself earns before the cost of selling it The spread between 7.7% and 29.5% on businesses that all sell reagents into hospitals is the most important fact in this chapter, and manufacturing cost does not explain it. What explains it is density and menu depth. QIAGEN runs a narrow, high-value menu with a very high attach rate and earns 29.5%. Siemens runs a broad platform estate across a large number of hospital laboratories, carries the field service cost of all of them, and earned 5.3% in fiscal 2024 before its transformation programme took it to 7.7% in fiscal 2025 – a 240 basis point improvement delivered mainly by cost reduction, not by price. The mechanism that sets price in most of the world The most important piece of value-chain mechanics in this market is a Chinese provincial document. Between 2023 and 2025 the Chinese healthcare security authorities moved in stages: a 25-province alliance for IVD reagents in 2023, a 28-province volume-based procurement covering tumour markers and thyroid function in 2024, and in 2025 the Anhui-led cardiac marker panel, the Gansu-led procurement of routine blood, stool and urine reagents – the first time routine laboratory products entered scope – and Jiangsu’s inclusion of non-invasive prenatal genetic testing services, the first time a testing service rather than a reagent was procured this way. National and provincial alliance items across the country were expected to exceed 700 in 2025. The Jiangxi biochemical reagent alliance published the outcome in January 2025: 154 manufacturers and 2,314 specifications awarded, at an average price reduction of 70%. The lowest winning bid in the alliance was RMB 0.03 per unit. Roche Diagnostics and Mindray both won lines at RMB 0.07. That is the single most consequential number in this report, and its value chain consequence runs in one direction. A 70% cut in the reagent price does not cut the manufacturer’s cost by 70%, so the margin on that line compresses almost to zero; the volume that the award confers is real, and the winner is the manufacturer with the lowest cost base. This is precisely why the domestic Chinese manufacturers gain share in a volume-based procurement and the multinationals do not: the multinational carries a global cost structure and a global price list, and the domestic manufacturer carries neither. In our interviews with procurement executives, the mechanism was described the same way repeatedly – the tender is not where the price is discovered, it is where the price is enforced. Where the margin actually accrues Roche’s 2025 diagnostics disclosure is the cleanest available map of where value sits inside a portfolio. Core Laboratory is the largest line at CHF 7.6 billion and it was flat for the year, with immunodiagnostics down 3% and clinical chemistry up 7%. Molecular Laboratory is a third of that size at CHF 2.5 billion and grew 4%. Pathology Laboratory is smaller still at CHF 1.7 billion and grew 14%, driven by companion diagnostics at +25% and advanced staining at +10%. Near Patient Care shrank, with blood glucose monitoring down 2% and the Liat point-of-care molecular line down 5%. Ranked by growth rather than by size, that portfolio inverts: the smallest and most specialised businesses – pathology and companion diagnostics – grow fastest, and the largest commodity business is flat. Ranked by revenue, the commodity business is four and a half times the size of the specialised one. The margin in this market accrues to the manufacturer who holds the specimen and the report, not to the one who holds the reagent bottle, and pathology is the position that holds the report. Two elements of the chain remain unquantifiable from disclosure and are named here rather than estimated: the cost of instrument service in geographies where placement density is low, which is carried inside the segment margin and never disclosed separately; and the cost of obsolescence when a platform is discontinued, which QIAGEN disclosed in 2025 as roughly USD 20 million of headwind from the NeuMoDx and Dialunox product exits. Both are real, both are larger in emerging markets, and neither appears in a gross margin. - **Model:** hybrid - **Distribution:** hybrid - **Supply Complexity:** Moderate ## Investment Activity Investment and Capital Formation This is a capital-light, cash-generative market that has spent the last three years consolidating and restructuring rather than building. The distinguishing feature of 2025 was not the size of the deals but what they were buying: installed base and menu, not technology. Who converts revenue into cash Participant 2025 cash and margin measure What it says Siemens Healthineers Diagnostics Adjusted EBIT EUR 333m, a 7.7% margin, from EUR 235m and 5.3% in fiscal 2024 A transformation programme can add 240 basis points without a price increase bioMerieux CEBIT EUR 728m at 17.9% of sales, up 16% at constant exchange rates Menu-led growth converts to margin Thermo Fisher Specialty Diagnostics Segment income USD 1,256m at 26.9% The highest margin in the peer set on a specialised menu QuidelOrtho Adjusted EBITDA USD 597m at 22.0%, up 240 basis points; GAAP net loss USD 1.13bn A USD 701m goodwill impairment is an accounting judgement about a past acquisition, not a 2025 trading result QIAGEN Adjusted operating margin 29.5%, up 80 basis points Tariffs and currency absorbed without margin loss Danaher Diagnostics Roughly USD 1bn of sustainable incremental annual revenue attributed to the Cepheid base Placement is the capital allocation decision that matters The pattern is consistent enough to state as a rule: in this market, margin comes from menu depth per placement, and cash comes from the density of the installed base. Siemens added 240 basis points of diagnostics margin by taking cost out of a broad estate. bioMerieux added margin by growing cartridges at 84% on a 110% larger installed base. QuidelOrtho held a 22% adjusted EBITDA margin while its revenue fell 2%, because 84% of that revenue was recurring. What the transactions were actually buying The strategically informative moves in this market are about portfolio shape rather than about acquiring capability. BD is separating rather than integrating. The proposed combination of BD’s Biosciences and Diagnostic Solutions businesses with Waters is expected to close around the end of the first quarter of calendar 2026, after which BD’s Life Sciences segment will be eliminated and BD will consist of four remaining segments. Diagnostic Solutions reported USD 1,838 million in fiscal 2025, down 0.4%. That is a company deciding that a USD 1.8 billion diagnostics unit is worth more inside a tools and instruments business than inside a medical products company. Werfen has already completed the same logic in reverse. It divested its medical devices business in July 2024 and its 2025 figures reflect exclusively in vitro diagnostics activity – EUR 2,131 million of sales, EUR 473 million of EBITDA, EUR 190 million of research and development at 9% of sales. A pure-play IVD company at a 22% EBITDA margin is the cleanest read available on what this market’s economics look like without a devices business attached. QIAGEN bought menu and sample technology. It completed the acquisition of Parse in December 2025 while discontinuing NeuMoDx and Dialunox at a cost of roughly USD 20 million of 2025 revenue. Buying a menu and killing a platform in the same year is a statement about where the return is: in assays that run on an installed base, not in another box. QuidelOrtho’s impairment is the cautionary case. A USD 701 million goodwill write-down in the third quarter of 2025, on a business that still produced a 22% adjusted EBITDA margin, is a reminder that the return on an acquisition in this market is decided by the installed base you inherit and the menu you can put on it, and not by the price you paid for the revenue. Capital intensity and the return problem Capital intensity in in vitro diagnostics is moderate and falling, and the reason is that the instrument is not the investment. Analysers are placed, leased or sold near cost; the consumables are bought as used; the marginal cost of an additional test is dominated by reagents and labour rather than by capacity. What is expensive is the assay menu and the regulatory programme that clears it – a fixed cost paid before any revenue exists, and the real barrier to entry in molecular and in specialised chemistry. That produces an unusual capital profile: an established platform business converts a high proportion of revenue into cash, and a business trying to enter a new discipline does not, whichever size it is. It also explains the direction of consolidation. Nobody in 2025 bought a technology that did not already have a menu and a placement. The scarcity in this market is not innovation and it has not been for a decade. It is the right to be on the bench. For a strategic acquirer the implication is that an IVD asset should be underwritten on installed-base density and menu coverage rather than on growth rate. For an investor, the observable that matters is the direction of reagent price per reportable result in the two largest markets: if China keeps resetting it and the United States keeps paying for the test rather than the reagent, the revenue line and the margin line will keep diverging, and 5.74% will be a forecast about the former only. - **Trend:** Consolidating - **Capital Intensity:** Moderate - **Recent M&A:** BD's proposed combination of its Biosciences and Diagnostic Solutions businesses with Waters, expected to close around the end of the first quarter of calendar 2026, after which BD's Life Sciences segment is eliminated; Werfen completed its exit from medical devices in July 2024 and now reports as a pure-play IVD company; QIAGEN completed the acquisition of Parse in December 2025 while discontinuing NeuMoDx and Dialunox at roughly USD 20 million of revenue cost; QuidelOrtho recorded a USD 701 million non-cash goodwill impairment in the third quarter of 2025; bioMerieux took a partial impairment of the VITEK REVEAL technology. ## Technology & Innovation Technology Insight: The Menu, the Cartridge and the Blood Test Four technology architectures do the work in in vitro diagnostics, and they are not generations of one another. They answer different questions, they are bought by different departments and they carry different economics – which is why this forecast grows at four different rates across them. Architecture one: the core laboratory platform A high-throughput analyser that runs immunoassay and clinical chemistry on the same track, usually the analytics engine of a hospital laboratory performing thousands of tests a day. Abbott’s Alinity, Roche’s cobas, Siemens’ Atellica and Beckman Coulter’s DxC and Access are the reference platforms. The technology is mature and the competition is not about chemistry: it is about automation, track connectivity, sample handling and the number of assays that can be run without stopping the line. This is where 40% of the market sits and where growth is closest to health system budget growth, because the alternative to buying more reagent is simply running the analyser for another shift. Architecture two: the cartridge Single-use, sealed, room-temperature-stable PCR or isothermal cartridges that non-specialist staff can run. This is the architecture that has changed the shape of the market over the last five years, and the disclosure is explicit about why. Danaher reports that Cepheid has tripled its installed base since the beginning of the pandemic, to more than 60,000 instruments, with more than 30 FDA-cleared assays and more outside the United States, and that this base carries roughly USD 1 billion of sustainable incremental annual revenue. bioMerieux’s SPOTFIRE – the small-footprint cartridge system – reached EUR 168 million of sales, up 84% in value and more than 100% in volume, with an installed base of 6,400 instruments, up 110%, while its larger BIOFIRE non-respiratory panels grew 10% to EUR 598 million with a net installed-base expansion of 1,800 units. The economics of the cartridge are the reason it grows at 8.5% while the core laboratory grows at 4.5%. A cartridge test is priced per episode, it is not commoditised by a reagent tender, and it moves a test to a setting where no laboratory exists – an emergency department, a physician office, a field clinic. Our field programme found the same pattern in every market we covered: the cartridge is adopted not because it is more accurate but because it removes a transport leg between the patient and the answer. Architecture three: the syndromic panel A multiplex panel that tests one specimen for fifteen to twenty pathogens at once. Its clinical proposition is antimicrobial stewardship – a result in an hour changes whether a broad-spectrum antibiotic is started – and that proposition is why the panel survives price pressure that destroys a single-analyte test. bioMerieux’s BIOFIRE franchise is the reference case, growing 10% in non-respiratory panels on an installed base that expanded by 1,800 instruments in a single year. The constraint is reimbursement rather than technology: a panel is paid for as one test or as several depending on the jurisdiction, and the difference determines whether the laboratory can afford to run it. Architecture four: the blood test that used to be a lumbar puncture The most consequential new IVD category of this decade arrived in 2025, and it is not a cancer test. The US Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in the diagnosis of Alzheimer’s disease: the Lumipulse G pTau217 and ss-Amyloid 1-42 Plasma Ratio, for adults aged 55 and over presenting with signs and symptoms of cognitive decline. In the clinical study supporting the clearance, 91.7% of individuals with a positive result had amyloid plaques confirmed by PET or cerebrospinal fluid, 97.3% of those with a negative result were confirmed negative, and fewer than 20% of the 499 patients tested received an indeterminate result. The agency was explicit that the test is not a screen and not a stand-alone diagnosis. Read the implications rather than the assay. Until this clearance, confirming amyloid pathology required a PET scan or a lumbar puncture. A plasma ratio on an existing immunoassay platform turns the highest-volume unmet diagnostic question in neurology into a routine blood draw, on installed instruments, at a reagent price. It does not require a new platform, a new laboratory or a new sales force. That is the ideal shape of an IVD product, and it is the reason the immunoassay and clinical chemistry segment is forecast to keep growing at 4.5% rather than at the rate of GDP: the menu on the installed base is still getting better. Why the technology is not the constraint Every capability required by this forecast already exists and is cleared. Quantitative PCR runs on 60,000 cartridge systems. Syndromic panels are routine. Sequencing costs have fallen far enough that panel price is not the constraint on molecular demand. Digital pathology imagers are installed and reimbursed in a growing number of jurisdictions – Roche’s advanced staining grew 10% and companion diagnostics 25% in 2025 on the strength of that shift. What constrains the market is menu approval and reimbursement, and both are slow. An assay must be cleared or registered, then coded, then covered, then adopted – four gates that each take quarters rather than weeks. The technology risk in this market is therefore almost zero and the execution risk is high. The correct question about any new IVD technology is not whether it works. It is whether the laboratory can bill for it. - **Innovation:** Moderate - **Patent Activity:** High - **Maturity:** Mature ## Market Risk Market Risk Assessment The risks that decide this market are administrative rather than clinical. The assays work and the volume is growing. What can remove revenue is a procurement award, a tariff, a coverage policy or a price administration – and every one of those is decided by an institution rather than by a competitor. Risk one: the Chinese price reset may not be finished Volume-based procurement moved from tumour markers and thyroid function in 2024 to cardiac markers and routine blood, stool and urine reagents in 2025. The Jiangxi biochemical alliance awarded 2,314 specifications at an average reduction of 70%. Routine haematology and urinalysis are the largest single block of this market’s volume, and they entered scope for the first time in 2025. The risk is not that the 2025 cut repeats. It is that the mechanism keeps extending – into immunochemistry, into microbiology, and now into testing services themselves, as Jiangsu did with non-invasive prenatal testing. Each extension resets a price that was previously negotiated. This is the single largest exposure in the forecast: if immunoassay and clinical chemistry grows at 2.5% rather than 4.5%, the 2033 market is USD 160.05 billion and the CAGR 5.04%. Risk two: the COVID tail is still in the comparator Abbott’s diagnostics division fell 4.5% organically in 2025 and would have grown 0.4% excluding COVID testing, because COVID sales fell from USD 176 million to USD 89 million in the fourth quarter alone. QuidelOrtho’s respiratory revenue fell 20% to USD 402 million on lower COVID testing. Roche’s point-of-care molecular line fell 5%. Every one of those is a comparator effect that will disappear, and every one of them depressed the base year. It is a risk to the reading of 2025 and an upside to the forecast, not a downside. Risk three: tariffs and industrial policy Siemens reported its fiscal 2025 margin against higher tariffs and cited them explicitly. Sysmex cut guidance from JPY 560 billion to JPY 535 billion citing US reciprocal tariffs and Chinese government procurement policy. QIAGEN absorbed tariffs and currency while still raising adjusted operating margin 80 basis points, which is the exception rather than the rule at smaller scale. A tariff on an instrument or a reagent is a cost that cannot be passed through in a tendered market, and it lands directly on the segment margin. Risk four: localisation is a share risk, not a price risk In a volume-based procurement the domestic manufacturer wins because it can survive a price the multinational cannot, and the multinational’s correct response – declining to bid – is a decision to lose the account. Over eight years the compounding consequence is not a lower price but a permanently smaller addressable share in the largest volume geography. Our interviews with procurement executives in Asia described domestic-first lists and localisation scoring as ordinary features of a tender rather than as exceptions, and that is a structural change in who can sell, not a cyclical change in what they earn. Risk five: the installed base is the forecast, and it can be displaced Every growth rate above volume growth in this model requires either new placements or a richer menu on the existing ones. A reagent annuity is a claim on an instrument that someone else can win back at the next tender cycle. The defence is the cost of switching, and that cost is falling as laboratories move to multi-vendor arrangements specifically so that they can re-tender without losing the platform. A market where the switching cost falls is a market where the annuity is worth less each year, and none of the participants discloses placement attrition in a way that would let a reader measure it. Risk six: menu commoditisation in molecular The highest-growth discipline in this forecast is also the one most exposed to commoditisation. A cartridge PCR test is technically hard to differentiate and increasingly easy to manufacture. The 8.5% growth rate for molecular assumes that syndromic panels and sequencing-based assays continue to command a premium over single-analyte PCR, and the evidence for that in 2025 was mixed: bioMerieux’s non-respiratory BIOFIRE panels grew 10% while Hologic’s Aptima CT/GC and HPV revenue fell on lower average selling prices as volumes grew with larger laboratory customers. Volume up and price down is not a premium market. What is not a risk Demand. Test volume is a function of population, age structure, clinical guidelines and the number of assays on the menu, and none of those is contracting. The cartridge installed base tripled in five years. The first blood-based Alzheimer’s test was cleared in 2025 and turns a PET scan into a reagent. Digital pathology is being reimbursed. The volume side of this market is not in question, which is precisely why the forecast is a price forecast in disguise. Overall market risk assessment: moderate. The growth forecast is well supported by installed-base and menu evidence, and the demand base is the most durable in healthcare. The revenue line is exposed to an administered price in the largest volume geography, to tariffs on a tendered product, and to a switching cost that is falling. Each of those is a policy variable, and policy variables move in both directions. - **Overall Risk:** Moderate - **Geopolitical Exposure:** High - **Substitution Risk:** Moderate ## Regulatory Landscape Regulatory and Policy Environment In vitro diagnostics is regulated twice: once as a device before it can be sold, and once as a price after it can be. The first gate is a registration and the second is a procurement, and in most of the world the second matters more to revenue. The operative frameworks European Union. Regulation (EU) 2017/746 on in vitro diagnostic medical devices replaced the previous directive and reclassified a large part of the assay population upwards, requiring notified body involvement where self-certification was previously sufficient. The practical consequences for this market are a longer time to market and a higher cost per assay, which structurally favours manufacturers with a large menu already placed and disadvantages the smaller manufacturer trying to add one assay. United States. A device requires clearance or approval – 510(k), De Novo or premarket approval – unless it is a laboratory-developed test performed in a laboratory certified under CLIA and accredited by the College of American Pathologists. That exemption was contested: a rule issued in May 2024 that would have phased laboratory-developed tests into device regulation was vacated in March 2025, and the agency reverted to its pre-2024 framework in September 2025. The distinction matters commercially, because a cleared device is a product a hospital buys and a laboratory-developed test is a service a laboratory sells – and only one of them is inside this report’s perimeter. China. Registration through the National Medical Products Administration is the entry gate, and since 2023 centralised volume-based procurement has been the price gate. The sequencing is what matters: the procurement began with tumour markers and thyroid function across 28 provinces in 2024, moved to cardiac markers under Anhui’s leadership and to routine blood, stool and urine reagents under Gansu’s in 2025, and extended to a testing service for the first time when Jiangsu’s non-invasive prenatal testing award took effect on 1 January 2025. Medical insurance price governance runs alongside it. Rest of world. WHO prequalification governs procurement by multilateral buyers, and the International Medical Device Regulators Forum framework has largely harmonised classification. The significance for this market is that an assay cleared in one jurisdiction is rarely sellable everywhere without a further registration, which is why the multi-regional manufacturer carries an advantage that is administrative rather than scientific. Three policy facts that move revenue in this market The price is set by a buyer, not by a seller. The Jiangxi biochemical alliance awarded 2,314 specifications at an average price reduction of 70%. A manufacturer cannot decline to participate without leaving the province, and cannot participate without accepting the price. This is the defining regulatory feature of the largest growth geography in the world and it is not a device regulation at all. Reimbursement of the test is separate from registration of the test. A cartridge panel can be cleared in a quarter and remain unbillable for years. The gates that decide whether a laboratory can afford to run an approved assay – a code, a payment rate, a coverage policy – sit with a different institution from the one that cleared it, and they move on a different clock. Industrial policy is now a procurement criterion. Localisation requirements in China, tariffs affecting instrument movement into the United States, and domestic-preference rules in several emerging markets all change the relative cost of an imported reagent against a locally manufactured one. Sysmex cited US reciprocal tariffs and Chinese government procurement policy in cutting its fiscal 2025 guidance from JPY 560 billion to JPY 535 billion. Siemens cited tariffs when reporting its fiscal 2025 margin. These are not regulatory hurdles in the traditional sense, and they move share faster than any registration decision does. What this means for the forecast The regulatory environment does not threaten the 5.74%. It shapes who captures it. A stricter device regime raises the cost of adding an assay, which protects the installed base of a large-menu manufacturer. A volume-based procurement lowers the price of a reagent, which transfers value from the manufacturer to the laboratory and favours the lowest-cost producer. The two forces push in opposite directions on margin and in the same direction on consolidation: in both cases, scale wins. - **Complexity:** High - **Approval Pathway:** Device registration before sale (EU IVDR notified body involvement, US 510(k) / De Novo / premarket approval with a vacated laboratory-developed-test rule, NMPA registration in China) followed by a separate payment gate: coding, coverage, and - in China - centralised volume-based procurement that sets the price administratively ## Frequently Asked Questions **Q: How large is the global in vitro diagnostics market?** USD 108.0 billion in 2025, forecast to reach USD 168.8 billion by 2033. That is a compound annual growth rate of 5.74%, a multiple of 1.56x, and USD 60.8 billion of incremental value across the eight-year window. The 2025 figure is a bottom-up construction from twelve attributed revenue pools worth USD 61.5 billion plus a stated residual of USD 46.5 billion, not an inherited headline number. **Q: Why did the IVD market grow only about 1% in 2025 if the forecast is 5.74%?** Because 2025 contained a one-time price reset in China, not a fall in test volume. Roche's China diagnostics sales fell 24% and its division grew 7% at constant exchange rates excluding China. Siemens, bioMerieux, Werfen and Sysmex all attribute part of their weakness to Chinese centralised procurement and government purchasing. A price administration resets the level once and does not compound, so a base year that contains it is artificially low. Volume growth was intact throughout: Abbott's Core Laboratory business grew 2.1% organically in the same year its diagnostics division fell 4.5%. **Q: What is inside the perimeter of this report and what is excluded?** Inside: reagents, kits, controls, calibrators and consumables sold for human clinical diagnostic testing; the instruments and software placed in clinical, hospital and reference laboratories; and the disciplines of immunoassay and clinical chemistry, molecular diagnostics, point-of-care and rapid testing, hematology, hemostasis, urinalysis, microbiology and blood culture, blood banking, and IVD-attributable histopathology and digital pathology. Excluded, and stated in the scope table: laboratory services revenue, research-use-only reagents, life science instruments and biopharma services, veterinary, food and environmental testing, industrial and pharma quality control, and medical imaging. **Q: Who are the largest participants in in vitro diagnostics?** On the attributed revenue in this report: Roche Diagnostics at USD 15,924 million, Danaher Diagnostics at USD 9,941 million, Abbott Diagnostics at USD 8,937 million, Siemens Healthineers Diagnostics at USD 4,912 million and Thermo Fisher Specialty Diagnostics at USD 4,676 million. Those five account for USD 44,390 million, or 41.1% of the base year. The twelve named participants account for 57.0%. The remaining 43.0% is a long tail of Chinese, Japanese, Korean, Indian and regional reagent manufacturers serving their own health systems.